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Inhaled corticosteroids for chronic obstructive 
pulmonary disease: what is their role in therapy?
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2Department of Pulmonary and 
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Abstract: Inhaled corticosteroids (ICSs) are a mainstay of COPD treatment for patients with 
a history of exacerbations. Initial studies evaluating their use as monotherapy failed to show an 
effect on rate of pulmonary function decline in COPD, despite improvements in symptoms and 
reductions in exacerbations. Subsequently, ICS use in combination with long-acting β
2
-agonists 
(LABAs) was shown to provide improved reductions in exacerbations, lung function, and health 
status. ICS-LABA combination therapy is currently recommended for patients with a history of 
exacerbations despite treatment with long-acting bronchodilators alone. The presence of eosino-
philic bronchial inflammation, detected by high blood eosinophil levels or a history of asthma or 
asthma–COPD overlap, may define a population of patients in whom ICSs may be of particular 
benefit. Prospective clinical studies to determine an appropriate threshold of eosinophil levels 
for predicting the beneficial effects of ICSs are needed. Further study is also required in COPD 
patients who continue to smoke to assess the impact of cell- and tissue-specific changes on ICS 
responsiveness. The safety profile of ICSs in COPD patients is confounded by comorbidities, 
age, and prior use of systemic corticosteroids. The risk of pneumonia in patients with COPD 
is increased, particularly with more advanced age and worse disease severity. ICS-containing 
therapy also has been shown to increase pneumonia risk; however, differences in study design 
and the definition of pneumonia events have led to substantial variability in risk estimates, 
and some data indicate that pneumonia risk may differ by the specific ICS used. In summary, 
treatment with ICSs has a role in dual and triple therapy for COPD to reduce exacerbations and 
improve symptoms. Careful assessment of COPD phenotypes related to risk factors, triggers, 
and comorbidities may assist in individualizing treatment while maximizing the benefit-to-risk 
ratio of ICS-containing COPD treatment.
Keywords: COPD, inhaled corticosteroids, bronchodilators, dual/triple therapy, safety, 
pneumonia
Plain-language summary
Increasing treatment options for COPD add to the complexity of treatment and require review of 
clinical data to inform treatment decisions. Inhaled corticosteroids (ICSs) in combination with 
long-acting β
2
-agonists (LABAs) reduce the risk of exacerbations and improve lung function 
and health status in patients with COPD compared with ICS or LABA therapy alone. Certain 
patients may particularly benefit from ICS therapy, including those with frequent exacerbations 
despite long-acting bronchodilator therapy and those with evidence of eosinophilic bronchial 
inflammation, which can be determined by high levels of blood eosinophils and/or a history of 
asthma or asthma–COPD overlap. Although relatively uncommon, an increased risk of pneu-
monia is associated with ICS use and appears to be dependent on the specific ICS used. Recent 
studies of triple therapy combining an ICS, LABA, and a long-acting muscarinic antagonist 
demonstrated significant benefits compared with dual therapy and support their widespread use 
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in COPD patients with frequent exacerbations, but longer-term data 
and comparisons of specific triple-therapy regimens are needed to 
optimize therapy.
History of inhaled corticosteroid 
use in COPD
COPD is characterized by persistent respiratory symptoms 
and progressive airflow limitation.1 Goals of COPD manage-
ment are to minimize the impact of symptoms, improve levels 
of physical activity, and decrease the future risk of exacerba-
tions responsible for disease progression.1 Achieving these 
goals is challenging due to the heterogeneous nature of COPD 
and an incomplete understanding of the pathophysiology of 
the disease. Inflammatory changes have been observed in 
the lungs as a result of inhaling cigarette smoke, as well as 
noxious particles and gases from other sources.1 The presence 
of increased numbers of inflammatory cells in airway biopsies 
and bronchoalveolar lavage, including neutrophils, alveolar 
macrophages, and T lymphocytes, in the lungs of smokers 
susceptible to the development of COPD may act directly on 
airway and alveolar tissue, promoting airway narrowing and 
airflow limitation.2,3 These data, in conjunction with the effec-
tiveness of inhaled corticosteroids (ICSs) in the treatment 
of asthma, encouraged routine use of ICSs in patients with 
COPD. Over the past three decades, extensive research has 
been conducted evaluating the use of ICSs in such patients. 
This article reviews the history of the use of ICSs in COPD, 
with a focus on pivotal clinical studies, systematic reviews, 
and meta-analyses. The effect of smoking on ICS response 
in COPD is also discussed, and safety considerations for ICS 
use in COPD are examined, particularly regarding long-term 
safety and pneumonia risk. The applicability of these data 
is considered in light of current treatment practices, as well 
as their relevance to future therapy for COPD, including 
triple-therapy regimens.
Use of ICS monotherapy in COPD
In the 1990s, short-term studies of ICS monotherapy in 
patients with COPD and chronic bronchitis found that anti-
inflammatory therapy reduced bronchial inflammation, but 
had varying effect on lung-function measures of forced 
expiratory volume in 1 second (FEV
1
) and peak expiratory 
flow (PEF).4–6 In a 6-month study, fewer exacerbations, par-
ticularly the most severe exacerbations, occurred in patients 
treated with ICSs compared with placebo.6 Subsequently, 
four long-term (3-year) randomized, placebo-controlled 
studies of ICS in patients with COPD were conducted to 
determine the effect of therapy on the rate of decline in pul-
monary function, the results of which are discussed further 
herein.7–10 These studies identified varying effects of ICSs 
on outcomes of interest in COPD, but failed to show ben-
efit of ICS monotherapy on pulmonary function (Table 1). 
A meta-analysis of ICS studies investigating lung function in 
patients with COPD showed that ICS use did not slow the 
rate of FEV
1
 decline in 3,571 patients over 24–54 months.11 
In addition, a subsequent pooled analysis of 3,911 patients 
showed that after 6 months, ICS therapy did not modify FEV
1
 
decline in patients with moderate-severe COPD.12
Lung Health Study II
Participants from the Lung Health Study smoking-cessation 
trial were recruited for a second study to assess the effect of 
triamcinolone acetonide in delaying decline in lung function 
in participants with COPD.7 A total of 1,116 smokers (or 
those who had quit smoking within the prior 2 years) with air-
flow obstruction, defined as an FEV
1
 to forced vital capacity 
(FVC) ratio ,0.70 and FEV
1
 30%–90% predicted, were 
enrolled. Although asthma diagnosis was not technically an 
exclusion criterion, patients who used bronchodilators or 
ICSs regularly were excluded, effectively excluding those 
with symptomatic asthma. The primary outcome measure, 
rate of decline in postbronchodilator FEV
1
, showed no sig-
nificant effect of ICS treatment vs placebo (44.2 vs 47.0 mL 
per year, respectively). Most respiratory symptoms, includ-
ing cough, phlegm, wheezing, and breathlessness, over the 
preceding year did not differ significantly between treatment 
groups at 36 months. Fewer new or worsening respiratory 
symptoms were found in the ICS group. The rate of unsched-
uled physicians’ visits and hospitalization for respiratory 
conditions was lower in the ICS group, but visits to the 
emergency department (for respiratory and nonrespiratory 
conditions) and all health-care visits (for nonrespiratory 
conditions) were similar between treatment groups. At base-
line, airway reactivity was similar between groups. At 9 and 
33 months, the ICS group had significantly less reactivity 
to methacholine challenge than placebo (P=0.02). Overall, 
health-related quality of life (measured by the SF36) showed 
no changes associated with treatment, except for a slightly 
worse mental health subscale score at 36 months in the ICS 
group compared with placebo.
european Respiratory Society study 
on COPD
Across nine European countries, 1,277 smokers aged 30–65 
years with postbronchodilator FEV
1
 50%–100% predicted 
and prebronchodilator FEV
1
:slow vital capacity ratio ,70% 
were randomized to receive budesonide dry-powder inhaler 
or placebo for 3 years.8 Patients with a history of asthma 
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were excluded. Changes in postbronchodilator FEV
1
 over 
the first 6 months were significantly different between ICSs 
(improved at a rate of 17 mL/year) and placebo (declined 
by a rate of 81 mL/year, P,0.001); however, by 9 months 
the slopes of FEV
1
 decline were similar between treatment 
groups (P=0.39). Among those who completed the 3-year 
study (n=912), the median decline in FEV
1
 over 3 years was 
140 mL in the ICS group and 180 mL in the placebo group 
(P=0.05). ICS use was more effective in patients who smoked 
less, but there was no association of the slope of FEV
1
 decline 
with age, sex, baseline FEV
1
, presence/absence of serum IgE 
antibodies, or reversibility of airflow limitation.
Copenhagen City Lung Study
Participants in the Copenhagen City Heart Study were eli-
gible for the lung study if they were aged 30–70 years, had 
an FEV
1
:FVC ratio #0.7, and had no self-reported asthma.9 
Smoking history was not an inclusion criterion, and long-term 
CS treatment (more than two episodes of .4 weeks duration) 
was the main exclusion criterion. A total of 290 patients were 
randomized to budesonide or placebo. There was no signifi-
cant effect of ICSs on rate of FEV
1
 decline, and stratification 
by sex, smoking status, and baseline FEV
1
 did not affect these 
results. No significant differences were observed between 
treatment groups for occurrence of symptoms, exacerbations, 
or reversibility to β
2
-agonist treatment.
Inhaled Steroids in Obstructive 
Lung Disease in europe (ISOLDe)  
study
Current or former smokers aged 40–75 years with non-
asthmatic COPD, FEV
1
:FVC ratio ,70%, baseline post-
bronchodilator FEV
1
 $0.8 L but ,85% predicted were 
eligible for the ISOLDE study.10 A total of 751 patients were 
randomized to fluticasone propionate or placebo. No signifi-
cant difference in annual rate of FEV
1
 decline was observed 
between ICSs and placebo (50 vs 59 mL/year, P=0.16), and 
slopes of decline were not influenced by smoking status, 
age, sex, or FEV
1
 response to oral CSs. The predicted mean 
FEV
1
 at 3 and 36 months was significantly higher with ICSs 
by 76 and 100 mL, respectively, vs placebo (P,0.001). The 
median yearly exacerbation rate was 25% lower for ICS 
vs placebo (0.99 vs 1.32 per year, P=0.026). In both treat-
ment groups, health status measured by the disease-specific 
St George’s Respiratory Questionnaire (SGRQ) improved 
after the first 6 months of treatment (slight decrease in 
SGRQ total score), but thereafter it worsened (increase 
in SGRQ score), and the rate of worsening was slower 
with ICSs than placebo (increase of 2.0 vs 3.2 units/year, 
respectively, P=0.004).
The results of these four studies consistently showed 
that ICS monotherapy did not reduce the accelerated rate 
of decline in pulmonary function that is characteristic of 
COPD, and thus ICS monotherapy is not disease-modifying. 
The only therapy proven to slow FEV
1
 decline in COPD is 
smoking cessation.13 However, ICSs improved some key 
secondary outcomes, including COPD symptoms, health-care 
utilization, airway reactivity, and notably the frequency of 
exacerbations. Systematic reviews of randomized controlled 
trials with at least 6 months of follow-up comparing ICS 
monotherapy vs placebo found a statistically significant 
reduction (18%–24%) in risk of exacerbations with ICSs.14,15 
Moreover, when the reduction in exacerbation risk by ICSs 
was regressed against initial FEV
1
 percentage predicted, it 
was found that the more severe the airflow obstruction, the 
greater the risk reduction.14 In addition, ICS therapy was 
also shown to decelerate the rate of worsening of health 
status measured by the SGRQ, with a 1.4-unit improvement 
(decrease in SGRQ score) relative to placebo.14 A Cochrane 
database review of randomized controlled trials comparing 
ICSs and placebo also showed the effect of ICSs on reduc-
ing exacerbations and slowing the rate of decline in health-
related quality of life.16 The ICS effect was not predicted by 
oral CS response, bronchodilator reversibility, or bronchial 
hyperresponsiveness.
The net impact of these studies in today’s world of com-
bination therapy for COPD is that effects of CSs, at least 
when administered alone, are often slow to develop, and 
responses in the first 6 months of therapy may not remain 
the same in the long term. Far fewer studies have been done 
on the effect of CS withdrawal in COPD, and few current 
combination-therapy studies require a 6-month washout prior 
to initiation of the trial.
Barnes et al reviewed cellular and molecular mechanisms 
of COPD pathogenesis and proposed several factors that 
may explain the limited response to ICS monotherapy in this 
disease.17,18 ICSs or oral CSs do not suppress inflammation in 
COPD, even at high dosages. In COPD, the numbers of airway 
neutrophils are increased, but they are not fully suppressed by 
CSs. In addition, resistance to CSs may be related to decreased 
activity and expression of HDAC2 in inflammatory cells of 
patients with COPD as a result of increased oxidative and 
nitrative stress from cigarette smoking. ICSs may have a 
small bronchodilator effect that is not disease-modifying, but 
additional investigation is warranted. The lack of significant 
efficacy on the rate of decline of FEV
1
 may have prevented 
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exploration of the dose response for ICSs in COPD.1 In 2014, 
a randomized, prospective study compared two dosages of 
fluticasone (500 and 1,000 µg/day) in patients with COPD 
and an FEV
1
:FVC ratio ,70%, FEV
1
 ,80% predicted, and 
smoking history .10 pack-years.19 The higher dosage was 
associated with improved lung function and symptoms, 
decreased exacerbations, and better quality of life compared 
to the lower dosage. In asthma, there is a tendency to admin-
ister higher dosages of ICS than needed for symptom control; 
however, this may increase the risk of adverse events, such as 
adrenal suppression, osteoporosis, and growth inhibition in 
children.20,21 Therefore, for US Food and Drug Administra-
tion (FDA) regulatory approval, efficacy differences between 
dosage groups must be demonstrated for COPD.22
Use of ICSs in combination with 
LABAs
Combining drugs with different modes of action may improve 
outcomes. Two-way synergistic activity between ICSs and 
LABAs has been demonstrated.23,24 One of the cellular actions 
of ICSs is to translocate glucocorticoid receptors from the 
cytoplasm to the nucleus.24 This action is enhanced in the 
presence of β-agonists and causes an anti-inflammatory effect 
greater than either drug alone, without the need to increase the 
ICS dosage.23 In addition, ICSs activate β-receptor genes to 
produce more β-receptors, thereby enhancing the bronchodi-
lator effect of LABAs.25 Numerous clinical studies have been 
conducted evaluating ICS-LABA combinations in patients 
with COPD, and systematic reviews and meta-analyses have 
pooled their results to inform treatment decisions. Relevant 
studies are discussed in the following paragraphs.
The Towards a Revolution in COPD Health (TORCH) 
trial was a pivotal, double-blind, placebo-controlled, random-
ized study comparing salmeterol plus fluticasone propionate 
(50 and 500 µg, respectively, taken twice daily) with each 
component alone and placebo over 3 years.26 Patients with 
COPD were enrolled if they had at least a 10-pack-year 
smoking history, FEV
1
 ,60% predicted, and an FEV
1
:FVC 
ratio #0.70.26 Among 6,184 randomized patients, the risk of 
death was reduced by 17.5% with the ICS-LABA combina-
tion vs placebo (P=0.052). ICS-LABA significantly reduced 
the rate of exacerbations by 25% compared with placebo 
(P,0.001) and improved health status and FEV
1
 compared 
with either component alone or placebo. A subsequent 
double-blind, randomized, parallel-group study included 
patients aged $40 years with COPD who had at least a 
10-pack-year smoking history, FEV
1
:FVC ratio #0.70, 
FEV
1
 #50% predicted, and at least one exacerbation in the 
past year requiring oral CSs, antibiotics, or hospitalization.27 
Among 782 randomized patients, a 30.5% reduction in mean 
annual rate of moderate-severe exacerbations was observed 
with salmeterol plus fluticasone propionate (50 and 250 µg, 
respectively) compared with salmeterol alone (P,0.001) at 
half the dose of fluticasone propionate used in the TORCH 
study.
In a 2003 review of three ICS-LABA combination-
therapy studies in COPD patients, a 30% reduction in 
exacerbations was observed vs placebo and trough FEV
1
 
improved vs placebo (101 mL/year, 95% CI 76–126) or either 
therapeutic agent alone (ICS 50 mL/year, 95% CI 26–74; 
LABA 34 mL/year, 95% CI 11–57).14 In two Cochrane 
database systematic reviews, ICS-LABA combination 
therapy administered in a single inhaler was compared to 
LABA or ICS monotherapy.28,29 Across nine eligible studies 
comparing ICS-LABA to LABA alone, the exacerbation rate 
was reduced by 24% (95% CI 0.68–0.84) with combination 
therapy, but there was no difference in mortality (OR 0.92, 
95% CI 0.76–1.11).28
In six studies that compared ICS-LABA vs ICS monother-
apy, a significant 13% reduction in the rate of exacerbations 
was noted (RR 0.87, 95% CI 0.80–0.94) and the odds of death 
were significantly lower with combination therapy (OR 0.78, 
95% CI 0.64–0.94).29 In addition, a 2014 Bayesian network 
meta-analysis evaluated randomized controlled trials of at 
least 12 weeks duration comparing fixed-dose ICS-LABA 
combinations with active control or placebo, and found that 
ICS-LABA reduced moderate-severe exacerbations, with 
the exception of beclomethasone dipropionate–formoterol, 
which had the lowest sample size of all groups (Figure 1).30 
HRs ranged from 0.59–0.92 for ICS-LABA vs placebo and 
0.63–0.98 for ICS-LABA vs LABA monotherapy. Medium- 
and high-dose ICS-LABA combinations were similarly effec-
tive in reducing the rate of moderate-severe exacerbations.
Estimates of treatment effect across these systematic 
reviews may have differed as a result of clinical trial het-
erogeneity, particularly with regard to baseline exacerbation 
history and lung function and how a COPD exacerbation was 
defined within a study.29,31 Despite these differences, a clear 
effect of ICS-LABA combination therapy on exacerbations 
was demonstrated, and the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) 2018 report concluded 
that ICS-LABA combination therapy was more effective 
than either agent alone in reducing exacerbations, as well as 
improving lung function and health status.1
Recent post hoc analyses of published trials have 
examined the early response to ICS-LABA combination 
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Figure 1 effectiveness of ICS-LABA inhalers.
Notes: Pooled effect estimates of combined ICS-LABA inhalers vs (A) placebo and (B) LABA on moderate-severe exacerbations. Copyright ©2014. Dove Medical Press. 
Reproduced with permission from Oba Y and Lone NA. Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD 
exacerbations: a Bayesian network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2014;9:469–479.30
Abbreviations: BDP, beclomethasone dipropionate; BUD, budesonide; CrI, credibility interval; FF, fluticasone furoate; FM, formoterol; FP, fluticasone propionate; ICS, 
inhaled corticosteroid; LABA, long-acting β2-agonist; MF, mometasone furoate; SAL, salmeterol; vI, vilanterol.
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of ICSs in reducing exacerbations.40–43 Dose–response 
effectiveness of ICSs has been demonstrated in patients with 
elevated eosinophils,44 and eosinophil levels may be able to 
direct treatment during COPD exacerbations. Eosinophilic 
inflammation in COPD, defined as sputum eosinophils $3%, 
has been reported in up to 28% of cases during an acute 
exacerbation and up to 38% of patients with stable disease.44 
However, measurement of sputum eosinophils is unsuitable 
for point-of-care testing and requires experience to dif-
ferentiate inflammatory cell counts. Measurement of blood 
eosinophils may be a more useful biomarker for routine 
practice. The threshold for eosinophilic inflammation contin-
ues to be debated, with some reports suggesting a threshold 
of .2%, 3%, or 4% of the total white-blood-cell count, 
whereas others propose a total eosinophil count of 150, 220, 
or 300 cells/µL.45,46
The INCONTROL study showed that for patients with 
blood-eosinophil counts $100 cells/µL, exacerbations were 
reduced significantly more with budesonide–formoterol 
compared with formoterol alone (P=0.015).42 The higher 
the blood-eosinophil count, the greater the exacerbation rate 
without ICSs and the greater the reduction in exacerbations 
with ICSs, which tends to reach a plateau around eosinophil 
counts of 400 cells/µL. The impact of blood-eosinophil count 
on response to ICSs was also found to be greater as the 
eosinophil count increased by Pascoe et al in their analysis 
of data from two parallel randomized controlled trials on the 
addition of fluticasone furoate to vilanterol.47
Disparate findings for blood eosinophils were reported 
in the Subpopulations and Intermediate Outcome Measures 
in COPD (SPIROMICS) cohort, in which blood eosinophils 
alone were not a reliable predictor of COPD exacerbations in 
contrast to sputum eosinophils, and the association between 
blood and sputum eosinophils was weak.48 Differences in study 
populations could account for the disparate findings, as the 
INCONTROL study had a larger number of smokers with more 
exacerbations compared with the SPIROMICS cohort.42,48
Elevated eosinophil counts in the blood and airway 
walls are also observed in patients with COPD who have 
other signs of inflammation.49 Tamada et al evaluated 331 
COPD patients for asthma-like airway inflammation or 
atopic factors using fractional exhaled nitric oxide and serum 
IgE, respectively.50 High fractional exhaled nitric oxide 
($35 parts per billion) was present in 16% of patients, high 
IgE ($173 IU/mL) occurred in 36% of patients, and both 
factors were present in 8% of patients. Furthermore, there 
is another type of COPD that occurs with asthma, termed 
therapy.32,33 Lower exacerbation rates and improved lung 
function (FEV
1
 and PEF) were evident as early as 3 months 
after starting treatment with budesonide–formoterol vs 
placebo. Early improvements in FEV
1
 and total score on 
the SGRQ were associated with future response, and early 
FEV
1
 improvements (but not SGRQ-score improvements) 
predicted lower risk of future COPD exacerbations.
Long-acting muscarinic antagonists (LAMAs), such as 
tiotropium, have a prolonged bronchodilator effect that has 
been shown to reduce exacerbations to a greater degree than 
LABA monotherapy.1,34,35 Despite being the most commonly 
prescribed first-line treatments, few clinical studies have 
compared LAMA monotherapy to ICS-LABA combination 
therapy.36 Using a large administrative claims database in the 
US, the real-world effectiveness of tiotropium was compared 
to budesonide–formoterol. The ICS-LABA combination 
reduced the risk of COPD exacerbation by 22% compared 
with LAMA monotherapy; however, the results could have 
been skewed by a high number of patients having possible 
comorbid asthma. The Investigating New Standards for 
Prophylaxis in Reducing Exacerbations (INSPIRE) study 
compared the efficacy of salmeterol–fluticasone with tiotro-
pium monotherapy in preventing exacerbations in patients 
with severe and very severe COPD.37 The exacerbation 
rate was not significantly different between the groups 
treated with ICS-LABA therapy and LAMA monotherapy, 
but the ICS-LABA group had better health status and was 
less likely to withdraw. The fact that LABAs and LAMAs 
work on different receptors to induce bronchodilation pro-
vides a rationale for their use in combination to optimize 
bronchodilation.38 The comparative efficacy of LAMA-
LABA (dual bronchodilators) vs ICS-LABA therapy in 
reducing exacerbations is currently a matter of keen interest. 
The Effect of Indacaterol Glycopyrronium vs Fluticasone 
Salmeterol on COPD Exacerbations (FLAME) study com-
pared the efficacy of a LAMA-LABA combination (gly-
copyrronium 50 µg–indacaterol 110 µg) with ICS-LABA 
(fluticasone 500 µg–salmeterol 50 µg) therapy in reducing 
exacerbation risk for patients with COPD.39 For patients with 
a history of exacerbation in the previous year, the annual rate 
of moderate or severe exacerbation was significantly lower 
for the LAMA-LABA group (0.98) than for the ICS-LABA 
group (1.19, P,0.001).
Predictors of response
Post hoc analyses suggest eosinophil counts in blood and 
sputum may be used as predictive biomarkers for the efficacy 
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asthma–COPD overlap (ACO). A clear definition of ACO 
has yet to be determined,50,51 but a systematic review and 
meta-analysis of 17 studies including COPD and asthma 
used a definition of any COPD patient with at least one of the 
following asthma characteristics: diagnosis of asthma, FEV
1
 
reversibility $12% and $200 mL of change from baseline, 
PEF variability $20%, and airway hyperresponsiveness to 
methacholine or histamine.51 Across the 17 studies, the pooled 
prevalence of ACO was 27% and 28% in population- and 
hospital-based studies, respectively. In five studies, ACO was 
associated with worse outcomes, including more frequent 
exacerbations, hospitalizations, and emergency-department 
visits, and two studies reported significantly higher use of 
ICS-LABA combinations in patients with ACO than those 
with COPD. Objective measures of airway inflammation 
and/or atopy (eg, IgE levels) indicate a smaller proportion 
of patients with ACO defined by symptoms, lung function, 
or physician diagnosis; however, these measures may be 
important for identifying patients who would benefit from 
ICS-LABA therapy.1 The presence of eosinophilic inflamma-
tion has not been studied extensively in this population.
Effect of smoking status on ICS 
response
Despite a causal link between cigarette smoking and COPD, 
a substantial percentage of patients with moderate-severe 
COPD continue to smoke (30%–43%).52 Sustained smoking 
cessation reduces the rate of decline in FEV
1
 and decreases 
respiratory symptoms among smokers with early COPD.53 
However, reductions in the amount of smoking up to 50% 
have no observable effect on the decline in FEV
1
, suggesting 
that total or near-total abstinence from smoking is required to 
reduce the effect of cigarette smoke on lung function.53
The adverse effects of smoking in patients with COPD or 
asthma have been attributed to increased airway inflammation 
and reduced CS responsiveness,54 but the majority of stud-
ies examining the effect of smoking on CS responsiveness 
have been conducted in patients with asthma.55 Although 
it has been proposed that the oxidative and nitrative stress 
associated with cigarette smoking may inactivate HDAC2 in 
COPD patients and contribute to ICS resistance,17 studies of 
smokers and ex-smokers generally have failed to identify a 
significant difference of ICSs on clinical and inflammatory 
parameters, including HDAC2.55,56 Reductions in bronchial 
mast cells have been observed with both short- and long-
term ICS treatment in smokers and ex-smokers with COPD, 
whereas reductions in CD3+, CD4+, and CD8+ cells were 
observed with short-term ICSs in current smokers only.55 
These differential effects of ICSs on specific cell types may 
be related to epigenetic regulation occurring with DNA 
methylation and histone modification.55 In a comparison of 
ICS therapy in smokers and ex-smokers with COPD, IL8 
and neutrophil-related elastase activity increased in smokers 
and were unchanged or decreased in ex-smokers.57 Sputum 
eosinophils may be reduced in smokers as a result of the nitric 
oxide and carbon monoxide present in cigarette smoke.54 A 
recent post hoc analysis of budesonide–formoterol studies 
in patients with COPD (INCONTROL) found that among 
current smokers, a greater reduction in exacerbation rate was 
observed with ICS-LABA therapy vs LABA alone at higher 
peripheral blood-eosinophil counts.42 These cell- and tissue-
specific responses may be related to the heterogeneous nature 
of COPD, and suggest that reduced steroid responsiveness 
is not a general characteristic of the disease.42,55 These find-
ings highlight the need for further evaluation of appropriate 
biomarkers of disease severity and treatment selection and 
their relationship to smoking status.
Safety considerations
A review of long-term studies of ICS monotherapy in 
patients with COPD revealed important information about 
their safety (Table 1). Skin bruising and oral candidiasis 
were increased with ICS therapy in most studies.7,8,10,43,58 In 
a subset of patients from the Lung Health Study, no effect of 
ICSs on adrenal function was observed over the 3-year study 
duration.59 These pivotal long-term studies of ICS mono-
therapy in COPD patients did not identify a difference in 
occurrence of cataracts compared with placebo.7,8,10 However, 
an increased risk of cataracts was observed in a population-
based, cross-sectional study of more than 3,000 patients, in 
which ICS use was associated with significantly increased 
prevalence of nuclear and posterior subcapsular cataracts, 
and higher cumulative lifetime doses were associated with 
higher risks.60 In a follow-up analysis 10 years later, the risk 
of incident cataracts was significant only for patients who 
had ever used both ICSs and oral CSs.61 Moreover, using a 
large electronic medical record database in the UK, ICSs or 
ICS-LABA (fluticasone propionate–salmeterol) combination 
therapy was not associated with increased risks of cataracts or 
glaucoma.62 The 1-year Efficacy and Tolerability of Budes-
onide/Formoterol in One Hydrofluoroalkane Pressurized 
Metered-Dose Inhaler in Patients with Chronic Obstructive 
Pulmonary Disease (SUN) study of budesonide–formoterol 
in COPD patients identified numerically more frequent 
adverse events typically associated with ICSs, including oral 
candidiasis, ocular effects, skin effects, and bone effects, 
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in the ICS-LABA group than the LABA-alone or placebo 
groups.63 However, there were no differences in objectively 
measured changes in lenticular opacity or intraocular pres-
sure, nor clinically relevant changes in bone-mineral density 
(BMD), across the three treatment groups.
Osteoporosis is a systemic feature of COPD, with preva-
lence that is two to five times higher than that in age-matched 
subjects without airflow obstruction.64 In a cross-sectional 
study of COPD patients, the dosage or duration of ICSs or 
oral CSs used was not different between those with osteo-
porosis and those with normal bone mass.64 Over the 3-year 
TORCH study, changes in BMD at the hip and lumbar spine 
were small, and there were no significant differences between 
any of the active treatment groups (ICS-LABA, ICS alone, 
LABA alone) and placebo.65 Long-term studies analyzed in 
the Cochrane database review did not show any major effect 
of ICS therapy on fractures or BMD over 3 years.16 In contrast, 
a meta-analysis of 16 randomized controlled trials (of which 
14 evaluated fluticasone and two budesonide) showed an 
increased risk of fractures (.20%) with more than 24 weeks 
of ICS therapy vs control.66 Significant reduction in BMD at 
the lumbar spine (1.33%, P=0.007) and femoral neck (1.78%, 
P,0.001) was observed with triamcinolone in the Lung 
Health Study,7,67 but not with budesonide in the  European 
Respiratory Society study (a small but significant decline in 
femoral trochanter BMD was observed with placebo vs budes-
onide, P=0.02).8 Current recommendations suggest measuring 
BMD in patients with COPD intermittently to assess fracture 
risk and treating those with significantly reduced BMD.68
Effect of ICSs on pneumonia risk in 
patients with COPD
The risk of pneumonia is increased in patients with COPD 
and further increased in those with a history of exacerbations 
and more severe disease.69,70 ICS-containing therapy for 
COPD has generally been associated with an increased risk 
of nonfatal pneumonia.70 A 2009 meta-analysis of 18 studies 
of ICS therapy in COPD estimated an approximately 60% 
increased risk of pneumonia without a significant increase 
in pneumonia-related death or overall mortality.71 In a new-
user cohort study using a medical record database, ICS use 
was associated with a 49% increased risk of pneumonia 
(vs long-acting bronchodilator) that was attenuated to 19% 
with at least 6 months of exposure.70
Differences in study design and duration, population 
studied, and definition of pneumonia events may contribute 
to variability in pneumonia rates across studies.69,70 Pneu-
monia risk may also differ by the specific ICS used. In the 
2009 meta-analysis, two of 18 trials evaluated budesonide 
at 800 µg/day, and 16 of 18 trials evaluated fluticasone pro-
pionate at dosages of 1,000 µg/day (N=10) or 250 µg/day 
(N=6). In a separate meta-analysis of seven large budesonide 
studies in COPD, no significant increased risk of pneumonia 
was determined with budesonide vs control of either placebo 
or formoterol (overall risk 1.05, 95% CI 0.81–1.37).72 The 
Investigation of the Past 10 Years Health Care for Primary 
Care Patients With Chronic Obstructive Pulmonary Disease 
(PATHOS) study investigated the incidence of pneumonia 
in patients with COPD using data from national Swedish 
health registries, comparing propensity-matched populations 
treated with budesonide–formoterol (N=2,734) and flutica-
sone–salmeterol (N=2,734).73 Patients in the fluticasone–
salmeterol group experienced an approximately 75% greater 
occurrence of pneumonia, including pneumonia requiring 
hospitalization, compared with the budesonide–formoterol 
group (P,0.001). Additionally, among patients using ICSs 
at baseline and followed for 4 years in the Understanding 
Potential Long-Term Impacts on Function with Tiotropium 
(UPLIFT) study, the risk of pneumonia was increased by 
.20% compared with those who did not use ICSs, but this 
increased risk was noted only in patients receiving flutica-
sone propionate and not in those using other ICSs (Table 2).74 
Fluticasone was also associated with a higher risk of any 
pneumonia, but not serious pneumonia, compared with 
budesonide in a Cochrane database review of 43 randomized 
controlled trials (26 fluticasone studies and 17 budesonide 
studies).75 Differences in outcome between ICSs and placebo 
may be due to uneven distribution of baseline characteristics 
because patients with more severe disease received more 
intensive treatment; however, patient subgroups based on 
the ICS they received were well matched, such that baseline 
characteristics cannot explain differences between flutica-
sone and other ICSs.74 Fluticasone differs structurally from 
beclomethasone and budesonide because it has a fluorine 
moiety, which leads to distribution in the lipid membranes 
and slower clearance from lungs and other tissue, which 
may impact lung immunity and inflammatory responses.74,76 
This study also suggested that the use of LAMA therapy 
may ameliorate some of the respiratory adverse effects of 
ICSs, supporting their use in combination.74 The absolute 
risk of pneumonia is low,77 and the authors’ experience sug-
gests that few physicians or patients avoid ICS therapy as 
a result of this risk. In summary, the physician and patient 
must consider the benefit of ICSs in reducing the future risk 
of exacerbations in relation to the increased pneumonia risk 
of ICS-containing therapy.70,72
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Role of ICSs in current COPD 
treatment
Large clinical trials and systematic reviews/meta-analyses 
of clinical trial data provide evidence for the development 
of COPD-treatment guidelines.1 Currently, GOLD guide-
lines provide recommendations for drug selection based on 
a patient’s symptom intensity and disease severity assessed 
by prior and future risk of exacerbations.1,45 ICS-LABA com-
binations have been shown to reduce exacerbations, improve 
lung function, and improve health status.14,26,28–30 ICS-LABA 
combinations are thus recommended as a treatment option for 
COPD patients with a history of frequent exacerbations,1 but 
they are commonly prescribed as first-line treatments, regard-
less of COPD severity.38,74 Over the past 5 years, there has 
been an increase in new drugs and delivery devices, adding 
to the complexity of COPD treatment options.45 However, the 
data reviewed herein provide information to identify patient 
groups that may benefit from ICS use (Figure 2). Concerns 
with ICS use are related to the safety considerations described 
in the previous section and the potential risks associated with 
withdrawal of ICS therapy.45,74,78 Long-term adverse events 
described in some studies are complicated by concomitant 
oral CS use and confounding disease severity, as well as 
comorbidities. It is important that exacerbations be differ-
entiated from other events that may be related to common 
comorbidities of COPD, including acute coronary syndrome, 
worsening congestive heart failure, pulmonary embolism, and 
pneumonia.1 Although for many years it was believed that 
stopping ICS use could trigger an exacerbation, it has recently 
been shown that withdrawal of ICSs is possible, particularly 
when other medications are introduced concomitantly.45 
In the Withdrawal of Inhaled Steroids during Optimized 
Bronchodilator Management (WISDOM) study, ICS therapy 
was withdrawn gradually over 12 weeks from a triple com-
bination, without an overall increased risk of exacerbations 
compared with the group that remained on triple therapy (HR 
1.06, 95% CI 0.94–1.19).79 However, in the group in which 
ICS therapy was withdrawn, FEV
1
 declined and health status 
tended to worsen significantly, albeit modestly, compared 
with patients who remained on ICS therapy. Moreover, in a 
subset of the overall patient population (~20%) with eosino-
phil counts $4% or $300 cells/µL, withdrawal of ICSs was 
associated with an increased risk of exacerbations.46 Still, for 
patients who are at low risk of exacerbation (ie, FEV
1
 .50% 
predicted, fewer than two exacerbations/year), ICSs can be 
withdrawn safely as long as maintenance LABA therapy is 
continued.80
Future directions: triple therapy and 
beyond
The step up to triple therapy with ICS + LABA + LAMA 
may improve lung function and patient-reported outcomes 
for COPD patients (eg, the addition of LAMA to ICS-
LABA reduces exacerbation risk).1 In the Single Inhaler 
Triple Therapy vs Inhaled Corticosteroid Plus Long-acting 
β
2
-Agonist Therapy for Chronic Obstructive Pulmonary 
Disease (TRILOGY) study of COPD patients with severe or 
very severe airflow limitation (ie, FEV
1
 ,50% predicted and 
at least one moderate or severe exacerbation in the previous 
12 months), triple therapy (beclomethasone dipropionate–
formoterol fumarate–glycopyrronium bromide) in a single 
inhaler significantly improved predose and postdose FEV
1
 and 
SGRQ total score and also reduced the exacerbation rate by 
23% compared with beclomethasone dipropionate–formoterol 
Table 2 Distribution of pneumonia events and incidence rates by treatment in the UPLIFT study
Treatment Events Years in study Incidence rate Incidence-rate 
ratio (95% CI)
P-value
Any ICS vs no ICS
No ICS 383 6,885 0.056 Reference
ICS 738 10,836 0.068 1.22 (1.08–1.38) 0.012
FP vs other ICS and no ICS
FP 437 5,685 0.077 1.38 (1.20–1.58) ,0.001
Other ICS 301 5,151 0.058 1.05 0.52
No ICS 383 6,885 0.056 Reference
Effect of Tio on pneumonia rate, irrespective of ICS
FP/Pbo 230 2,720 0.081 1.45 (1.19–1.77) ,0.001
FP/Tio 217 2,964 0.073 1.31 (1.08–1.60) 0.006
Other ICS/Pbo 153 2,461 0.062 1.12 (0.90–1.38) 0.29
Other ICS/Tio 148 2,690 0.055 0.99 (0.79–1.23) 0.94
No ICS/Pbo 184 3,317 0.055 Reference
No ICS/Tio 199 3,567 0.056 1.00 (0.82–1.22) 0.95
Note: Reproduced with permission from Morjaria JB, Rigby A, Morice AH. Inhaled corticosteroid use and the risk of pneumonia and COPD exacerbations in the UPLIFT 
study. Lung. 2017;195(3):281–288. Creative Commons license and disclaimer available from: http://creativecommons.org/licenses/by/4.0/legalcode.74
Abbreviations: FP, fluticasone propionate; ICS, inhaled corticosteroid; Pbo, placebo; Tio, tiotropium.
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Figure 2 The role of ICS in patients with COPD.
Notes: Eosinophil thresholds for beneficial ICS effect are discussed in the text. Data regarding the effect of ICS on comorbidity presence or course are limited.
Abbreviations: ACO, asthma–COPD overlap; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; wBCs, white blood cells.
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Figure 3 COPD exacerbations in the TRILOGY study.
Notes: Unadjusted annual rate of COPD exacerbations of differing severity in the intent-to-treat population for the TRILOGY study. Reprinted from The Lancet, 388(10048), 
Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease 
(TRILOGY): a double-blind, parallel group, randomised controlled trial, Pages 963–973, Copyright 2016, with permission from elsevier.81
Abbreviations: BDP, beclomethasone dipropionate; FF, fluticasone furoate; GB, glycopyrronium bromide.
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fumarate (Figure 3).81 Patients enrolled in this study could have 
been receiving ICS-LABA, ICS-LAMA, or LABA-LAMA 
combination therapy or LAMA monotherapy and entered a 
2-week run-in phase in which they received ICS-LABA prior 
to randomization. As such, escalation from LABA-LAMA 
therapy directly to triple therapy needs to be evaluated. 
The recently published Lung Function and Quality of Life 
Assessment in COPD with Closed Triple Therapy (FULFIL) 
study results support a benefit of single-inhaler triple therapy 
compared with ICS-LABA for lung function, health status, 
and exacerbation rate at 24 weeks.82 Moreover, results of 
the Informing the Pathway of COPD Treatment (IMPACT) 
study demonstrated that the triple combination of fluticasone 
furoate–umeclidinium–vilanterol reduced the rate of moder-
ate or severe exacerbations more effectively than both the 
ICS-LABA (fluticasone furoate–vilanterol, 15% difference, 
P,0.001) and the LABA-LAMA (umeclidinium–vilanterol, 
25% difference, P,0.001) combinations.83 Interestingly, these 
results imply that ICS-LABA might be superior to LABA-
LAMA in reducing exacerbations in this .10,000-patient 
study, in direct contrast to the findings from the FLAME 
study.39 A number of factors may have contributed to the 
disparate findings in the IMPACT and FLAME studies, 
including different patient populations, study-design differ-
ences for the run-in period and ICS withdrawal, and different 
methods of statistical analyses of end points. More data are 
needed to determine appropriate patient selection criteria for 
ICS-LABA, LABA-LAMA, and triple-therapy regimens.
In contrast to these positive results for triple therapy, a 
2015 systematic review and meta-analysis of seven trials of 
triple therapy using tiotropium and an ICS-LABA fixed-dose 
combination in a separate inhaler vs tiotropium monotherapy 
showed no significant benefit for triple therapy on mortality or 
exacerbations.84 Improvement in FEV
1
 and SGRQ score was 
greater with triple therapy, but lower than the minimal clinically 
important difference. Six of the seven trials were #24 weeks 
in duration. These findings highlight potential differences in 
triple-therapy regimens, the need for studies of longer duration, 
and the impact of single inhalers (presumably as a result of 
increased adherence) compared with multiple inhalers. Indeed, 
the use of multiple inhalers adds complexity to the treatment 
regimen, especially when considering the different types of 
inhalers currently available and patient preferences.85
An analysis of prescribing patterns in the UK indicated 
that 32% of patients received triple therapy between 2002 and 
2010, regardless of GOLD severity category.86 Few patients 
in GOLD groups A, B, C, or D (as defined in the 2011 GOLD 
report) received triple therapy prior to or at initial diagnosis, 
but after initial diagnosis, prescriptions for triple therapy 
occurred in 19%, 28%, 37%, and 46% of patients in GOLD 
groups A, B, C, and D, respectively.86 The most frequent 
treatment-escalation pathway was from ICS-LABA to triple 
therapy. Therefore, the majority of COPD patients may be 
overtreated compared with GOLD guidelines, with 75% of 
those receiving triple therapy having only mild or moderate 
COPD.87,88 However, it is important to note that there have 
been no studies to evaluate the use of aggressive treatment 
to reduce COPD exacerbations followed by de-escalation of 
the therapy. Triple therapy may allow the assumption that a 
patient is receiving optimal treatment for COPD with optimal 
bronchodilation via two mechanisms plus anti-inflammatory 
effects.86 In addition, triple therapy does not appear to be 
associated with a greater risk of adverse events compared 
with ICS-LABA or LAMA monotherapy.81,84
Fluticasone furoate–umeclidinium–vilanterol inhalation 
powder (Trelegy Ellipta; GlaxoSmithKline, Research Tri-
angle Park, NC, USA) was recently approved by the FDA as 
the first once-daily single-inhaler triple therapy for COPD.89 
Combination triple therapy in a single inhaler may increase 
the likelihood of better adherence,85 but it also increases the 
expense of the product in the absence of generic equivalents.45 
National Institute for Health and Care Excellence guidelines 
state that triple therapy is cost-effective only in patients who 
have FEV
1
 ,50% predicted and frequent exacerbations (two 
or more in past 12 months).86,90 In this regard, it is interest-
ing that only 2.1% of patients in the SPIROMICS cohort, of 
whom 30% had severe airflow obstruction, had two or more 
exacerbations in each year over a 3-year period.91 Therefore, 
the frequent exacerbator phenotype appears to be much less 
common than reported in the Evaluation of COPD Longitudi-
nally to Identify Predictive Surrogate End-points (ECLIPSE) 
study.92 Accurate assessment of exacerbation history and 
future risk is thus necessary to guide individualized therapy 
decisions in patients with COPD.
For patients with COPD who continue to experience 
exacerbations while receiving LABA-LAMA-ICS therapy, 
the addition of a phosphodiesterase 4 inhibitor or macrolide 
antibiotic has been recommended.1 Moreover, therapeutic 
agents targeting eosinophils, namely anti-IL5 and anti-
IL5-receptor monoclonal antibodies, have been evaluated 
to reduce the risk of exacerbations in COPD patients with 
high eosinophil counts and a history of exacerbations despite 
optimized standard-of-care therapy;43 however, results have 
been inconsistent.93–95
Overall, the use of ICSs in dual and triple therapy for 
COPD has been shown to reduce exacerbations and improve 
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symptoms. Furthermore, individualizing therapies based on 
each patient’s phenotype, including risk factors and comor-
bidities, has the potential to maximize the benefit:risk ratio 
of COPD treatment.
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